RedHill Biopharma (RDHL) Gross Profit (2014 - 2023)

RedHill Biopharma (RDHL) has 9 years of Gross Profit data on file, last reported at $990000.0 in Q2 2023.

• On a quarterly basis, Gross Profit fell 89.41% year-over-year to $990000.0 in Q2 2023; TTM through Jun 2023 was $15.3 million, a 51.16% decrease from a year earlier, with the FY2025 full-year figure at $5.5 million, up 13.67% from the prior year.
• Gross Profit for Q2 2023 stood at $990000.0, down from $2.0 million in the prior quarter.
• Over the last five years, Gross Profit for RDHL reached as high as $12.4 million in Q3 2021 and fell as low as -$659000.0 in Q1 2020.
• Historically, Gross Profit has averaged $5.5 million across 5 years, with a median of $5.5 million in 2020.
• Across the five-year window, Gross Profit tumbled 149.92% in 2020 and jumped 1666.31% in 2021, its largest moves.
• Year by year, Gross Profit stood at $802000.0 in 2019, then soared by 1247.76% to $10.8 million in 2020, then slumped by 74.68% to $2.7 million in 2021, then jumped by 53.45% to $4.2 million in 2022, then slumped by 76.43% to $990000.0 in 2023.
• Per Business Quant data, the three most recent Gross Profit figures were $990000.0 in Q2 2023, $2.0 million in Q1 2023, and $4.2 million in Q4 2022.